Montelukast and Telmisartan as Inhibitors of SARS-CoV-2 Omicron Variant

Earlier studies with montelukast (M) and telmisartan (T) have revealed their potential antiviral properties against SARS-CoV-2 wild-type (WT) but have not assessed their efficacy against emerging Variants of Concern (VOCs) such as Omicron. Our research fills this gap by investigating these drugs’ im...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulgaonkar, Nirmitee, Wang, Haoqi, Zhang, Junrui, Roundy, Christopher M., Tang, Wendy, Chaki, Sankar Prasad, Pauvolid-Corrêa, Alex, Hamer, Gabriel L., Fernando, Sandun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385313/
https://www.ncbi.nlm.nih.gov/pubmed/37514075
http://dx.doi.org/10.3390/pharmaceutics15071891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385313/
https://www.ncbi.nlm.nih.gov/pubmed/37514075
http://dx.doi.org/10.3390/pharmaceutics15071891

Ejemplares similares